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The  current  control  method  for contagious  bovine  pleuropneumonia  (CBPP)  in Africa  is  vaccination  with
a live,  attenuated  strain  of Mycoplasma  mycoides  subsp.  mycoides  (Mmm).  However,  this method  is  not
very  efﬁcient  and  often  causes  serious  adverse  reactions.  Several  studies  have  attempted  to  induce  pro-
tection  using  inactivated  mycoplasma,  but  with  widely  contradictory  results.  Therefore,  we comparedeywords:
ontagious bovine pleuropneumonia
nactivated vaccine
ycoplasma mycoides subsp. mycoides
the  protective  capacity  of the  live  T1/44  vaccine  with  two inactivated  preparations  of Mmm  strain  Afadé,
inoculated  with  an  adjuvant.  Protection  was  measured  after  a challenge  with  Afadé.  The  protection  levels
were  31%,  80.8%  and  74.1%  for the  formalin-inactivated,  heat-inactivated  and  live  attenuated  prepara-
tions,  respectively.  These  ﬁndings  indicate  that  low  doses  of heat-inactivated  Mmm  can  offer  protection
to  a level  similar  to  the  current  live  attenuated  (T1/44)  vaccine  formulation.
© 2016  The  Authors.  Published  by  Elsevier  B.V.  This  is  an  open  access  article  under the  CC  BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).. Introduction
Contagious bovine pleuropneumonia (CBPP) is a respiratory dis-
ase of cattle caused by Mycoplasma mycoides subsp. mycoides
Mmm)  and listed by the World Organization for Animal Health
OIE, 2014) as one of the most economically important livestock
iseases in Africa.
Currently, a live attenuated culture of the causative organism
train T1/44 is used as a vaccine of choice. Although it confers some
evel of immunity, the T1/44 vaccine has certain drawbacks that
nclude low efﬁcacy (Thiaucourt et al., 2000) and a short duration of
mmunity. Further, the vaccine causes adverse post-vaccinal reac-
ions at the site of inoculation leading to poor acceptance by farmers
Kusiluka and Sudi, 2003; Sori, 2005). Finally, the vaccine has poor
tability (short shelf life), hence the requirement for a cold chain
uring delivery (Rweyemamu et al., 1995) and there is the possi-
ility of reversion to virulence (Mbulu et al., 2004). For this reason,
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/).an efﬁcient inactivated vaccine would be a useful addition to the
existing prophylactic measures.
Vaccinations using inactivated vaccines have been successful in
a number of mycoplasma diseases including contagious agalactia
(Buonavoglia et al., 2008) and contagious caprine pleuropneu-
monia (Rurangirwa et al., 1987). Similar trials for CBPP with a
saponin-inactivated vaccine (Nicholas et al., 2003) and with an
Immunostimulating Complex (ISCOM) formulation (Hübschle et al.,
2003) have not yielded success.
The inactivation method and quantity of mycoplasma admin-
istered may play an important role. Inactivation by heat or by
sodium hypochlorite can substantially alter the antigens from
Mycoplasma agalactiae and hence reduce the immunogenicity (Tola
et al., 1999). However, two  doses of 20 ml  at a protein concentra-
tion of 14.5 mg/ml  of heat inactivated mycoplasma formulated with
a suitable adjuvant induced immunity against CBPP (Gray et al.,
1986). This suggests that mycoplasma may  have to be present in
large numbers, either alive or dead, to induce a sufﬁcient protec-
tive response and conﬁrms that an inactivated vaccine can confer
immunity. Protection by the live T1 strain of Mmm  has also been
shown to be dose dependent, with a low dose of 105 mycoplasma
conferring low protection, while there was no signiﬁcant difference
under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.
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etween doses of 107 and 109 (Gilbert and Windsor, 1971; Masiga
t al., 1978; Thiaucourt et al., 2000).
Owing to the discrepancies in reports on the capacity of
nactivated mycoplasma to protect against CBPP, three vaccines
ormulations were assessed for their protective capability: forma-
in inactivated (Garba and Terry, 1986) and heat inactivated (Gray
t al., 1986) vaccines were compared with the live attenuated T1/44
accine. The main purpose of the study was to evaluate the efﬁ-
acy of inactivated mycoplasma and compare formalin-ﬁxed and
eat-inactivated formulations, using equal quantities of antigen.
e used the vaccine preparations that yielded the best results in
he previous studies.
. Materials and methods
.1. Cattle
Forty Boran cattle (Bos indicus)  between 8 and 10 months of age
ere obtained from the International Livestock Research Institute
ILRI) ranch in Kapiti, a CBPP-free region in Kenya, and transported
o an isolation unit at Kenya Agricultural and Livestock Research
rganisation, Veterinary Science Research Institute (KALRO-VSRI) -
uguga. During the whole period of the experiment, animals were
andled according to Kenya legislation for animal experimenta-
ion and VSRI Animal Welfare Committee regulations (Approval No.
ALRO/VRC/IACUC/2/00122010).
.2. Vaccine preparation
.2.1. Formalin inactivation
The vaccine was prepared as previously described (Garba and
erry, 1986). Brieﬂy, the vaccine was prepared from a pure 4-day
ld culture of the Afadé strain using pleuropneumonia-like organ-
sm media (DifcoTM PPLO Broth) and harvested by centrifugation
t 12,000 g and reconstituted to a concentration of 1010 colony
orming units per millilitre, as assessed by colour changing units
CCU) (Litamoi et al., 1996). The culture was inactivated by adding
.7% (v/v) of formaldehyde (BDH Chemicals Ltd, Poole, UK) and
ncubated overnight at 37 ◦C. The suspension contained 3 mg/ml
f protein as determined using the Bicinchoninic Acid method. The
reparation was then stored at +4 ◦C until used. The ﬁnal product
as obtained by emulsifying equal volumes of inactivated culture
nd of Freund’s Incomplete Adjuvant (FIA; Difco).
.2.2. Heat inactivation
Preparation of the vaccine was done as described (Gray et al.,
986). The Afadé strain of Mmm  was grown for 4 days in PPLO
edia (Difco)  to a concentration of 1010 CCU/ml and centrifuged at
2,000 g. The pellet was washed three times in phosphate buffered
aline (PBS). and re-suspended in 10 ml  of the same solution. Pro-
ein concentration was then determined using the Bicinchoninic
cid Assay. This suspension was adjusted to contain 3 mg/ml  of
ycoplasma protein. Mycoplasma were killed by heating in a water
ath at 56 ◦C for 30 min. To determine if there was  any viable
ycoplasma left, 1 ml  of the suspension was dispensed in 9 ml
rowth media and observed for any colour change. No colour
hange was observed after 8 days and hence the killed mycoplasma
as then kept at −20 ◦C until the day of immunization. On the day of
accination, an equal volume of Freund’s Complete Adjuvant (FCA;
ifco) was added and mixed by means of an emulsion mixer. The
rops of mixed emulsion did not disperse on the surface of PBS..2.3. Live attenuated (T1/44)
Contavax (B/No. 01/2012) (Kenya Veterinary Vaccine Produc-
ion Institute) at a concentration of 107 live Mycoplasma perd Immunopathology 169 (2016) 63–67
animal was  used. Immunization was  done as instructed by the
manufacturer.
2.3. Experimental design
Cattle were randomly divided into four groups of ten animals,
one of which comprised the non-immunized control group. On
day 0 of the immunizations, groups 1 and 2 were inoculated
with heat-inactivated, formalin-inactivated and live attenuated
(T1/44) vaccine, respectively. Each animal was  subcutaneously vac-
cinated with 2 ml  of the vaccine formulation on the neck. Animals
received a primary immunization with Freund’s complete adju-
vant for the heat-inactivated mycoplasma or Freund’s incomplete
adjuvant for the formalin-ﬁxed mycoplasma. After three weeks,
two booster injections, separated by 2 months, were delivered
with the inactivated mycoplasma mixed with Freund’s incom-
plete adjuvant in both groups. Group 3 was inoculated with a
single dose of live T1/44 on day 0 of the immunizations. Dur-
ing the experiment ﬁve animals died of causes not related to
CBPP.
2.4. Challenge and clinical observations
Three weeks post the second booster administration, cattle
were challenged by endotracheal intubation of 60 ml  of Mmm  cul-
ture (approximately 109 CCU/ml) following the method described
(Nkando et al., 2010).
The cattle were restrained in a crush daily at the same hour
(09:00–10:00 am)  for clinical observation. Rectal temperatures,
coughing and general condition were recorded daily.
2.5. Serological examination
The animals were bled immediately before vaccination and at
weekly intervals during the trial period. Blood samples were taken
from the jugular vein into vacutainer tubes and allowed to clot
at room temperature overnight. Following separation by centrifu-
gation, serum samples were collected and stored at −20 ◦C until
examined by the complement ﬁxation test (CFT) (Campbell and
Turner, 1953).
2.6. Post-mortem examination, mycoplasma isolation and lesion
scoring
Post-mortem was carried out on all the animals 56 days after
challenge. The cattle were euthanized by captive bolt and then
exsanguinated. Lungs were examined for CBPP lesions including
encapsulation, consolidation, ﬁbrous adhesion and sequestration.
The type and size of the lesion was  recorded.
Lung tissues were collected between the lesion and the grossly
normal tissue and stored at -20 ◦C until culturing for mycoplasma
was done. Culturing of Mmm from the lungs was done by incubat-
ing a small piece of the lung tissue in Gourlay broth media (with
penicillin and thallium acetate) at 37 ◦C in a humidiﬁed 5% CO2
incubator. One milliliter of the suspension was titrated in a dilu-
tion series (1:10, 1:20, 1:30 and 1:40) after one day of growth.
From these dilutions, 0.2 ml  was  then dropped onto agar plate with
Gourlay media and incubated at 37 ◦C. Morphological features and
typical “fried egg” appearance checked at days 1, 5 and 10 for Mmm
colonies.
Lesion scoring (Hudson and Turner, 1963) was used to deter-
mine the severity of the disease in each animal. This scoring was
done as follows;
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1) Presence of only encapsulated, resolving or ﬁbrous lesion or
pleural adhesion: 1 - Or if presence of other type of lesion like
consolidation, necrosis or sequestration: 2
2) Mmm  isolated: 2
The resulting sum of the score (maximum 4) was  multiplied by
 factor depending on the lesion size (1: < 5 cm;  2: > 5 and < 20 cm;
: > 20 cm in diameter). Protection rate was calculated as follows:
Vaccine efﬁcacy = 1 − [mean score of vaccinates/mean score of
ontrols] × 100
.7. Statistical analysis
Analysis of variance (ANOVA) was used to determine if there
ere differences in CFT titres following vaccination between the
hree vaccinated groups. Pearson correlation coefﬁcient was  used
o analyse relationship between CFT titres and pathology score.
athology scores were evaluated to determine if there was  a dif-
erence in protection afforded by the three vaccines. Differences
etween mean pathology scores in the four groups (vaccinates and
ontrols) were also analysed using ANOVA. To evaluate differences
etween the antibody response as revealed by CFT was  performed
sing Chi-square (2) test. Prism statistical software (6th edition)
as used in the analysis.
able 1
linical and pathological results in animals vaccinated with inactivated and T1/44 vaccin
Vaccination
group
Animal No. Respiratory distress
(coughing) observed
Heat-
inactivated
819 Yes 
802  Yes 
825  No 
815  Yes 
813  No 
803  Yes 
824  Yes 
804  Yes 
806  Yes 
Formalin-
inactivated
807 Yes 
827  Yes 
814  Yes 
800  Yes 
801  Yes 
823  Yes 
810  No 
Live  attenuated
(T1/44)
808 Yes 
812  No 
811  Yes 
805  No 
816  Yes 
828  Yes 
820  Yes 
829  No 
Control group 842 No 
843  No 
844  No 
990  Yes 
991  Yes 
992  Yes 
993  Yes 
994  Yes 
995  Yes 
996  No 
ons = consolidation; ﬁb adhe = ﬁbrous adhesion; res adhe = resolving adhesion, Res les = Rd Immunopathology 169 (2016) 63–67 65
2.8. Results and Discussion
This study compared the protective capacity of the live T1/44
vaccine with two  inactivated preparations of Mmm  strain Afadé,
formulated with adjuvants. Both the heat (Gray et al., 1986b) and
formalin (Garba and Terry, 1986) inactivated vaccine formula-
tions had been shown to have complete protective capacity. The
heat-inactivated mycoplasma emulsiﬁed with complete Freund’s
adjuvant, was used at a concentration of 14.5 mg of protein/ml
and 10 ml were used during vaccination (Gray et al., 1986b). The
formalin inactivated 0.5 ml  dose of 1010 mycoplasma/ml was pro-
tective against CBPP. In the present experiment a uniform dose of
3 mg/ml  of proteins was used in the heat and formalin inactivated
vaccine formulations while T1/44 was  used as instructed by the
manufacturer.
2.9. Clinical observations
Animals under study had no clinical signs prior to challenge.
Clinical responses observed after challenge included cough, nasal
discharge and fever (in this study considered to be ≥39.5 ◦C). A
high number of animals in all the groups experienced respiratory
distress characterised by coughing (Table 1). This was observed
from the second week post intubation except for the group receiv-
ing formalin-ﬁxed organisms that experienced symptoms from the
es.
Mmm isolated Lung/Thoracic cavity
lesions (cm)
Pathology Score
−ve No lesion 0
−ve No lesion 0
−ve No lesion 0
−ve Cons 2
−ve No lesion 0
−ve Fib adhe 1
−ve No lesion 0
−ve Fib tags 1
−ve Fib adhe 1
No lesion
+ve Seq (3x3) 4
−ve No lesion 0
−ve Cons 2
−ve No lesion 0
−ve Cons 2
+ve seq (10x7) 6
−ve No lesion 0
+ve No lesion 2
−ve Cons 2
−ve No lesion 0
−ve No lesion 0
+ve No lesion 2
−ve No lesion 0
−ve No lesion 0
+ve No lesion 2
+ve cons 4
+ve No lesion 2
+ve Fib adhe, hep 4
+ve Fib adhe, cons 4
+ve cons 4
+ve cons 4
+ve No lesion 2
−ve Res les 1
−ve No lesion 0
−ve cons 2
esolving lesion; cong = congestion; Seq = sequestration.
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Table 2
Serology after vaccination and challenge.
Vaccination
group
Animal No. Highest CF titre
after vaccination
and before
challenge
Highest CF titre
after challenge
Heat-
inactivated
819 1:20 1:80
802 1:40 1:20
825 1:40 1:40
815 1:40 1:40
813 1:40 1:20
803 1:40 1:20
824 1:40 1:20
804 1:40 1:20
806 1:20 1:20
Formalin-
inactivated
807  1:40 1:40
827 1:40 1:40
814 1:10 1:40
800 0 0
801 1:80 1:40
823 1:20 1:40
810 0 0
Live  attenuated
(T1/44)
808 1:10 0
812 0 0
811 0 0
805 1:20 1:40
816 0 1:20
828 0 1:40
820 0 0
829 1:20 0
Control group 842 – 0
843 – 0
844 – 0
990 – 0
991 – 1:80
992 – 0
993 – 0
f
g
T
w
s
2
c
r
T
9
h
v
T
V994 – 0
995 – 1:160
996 – 0
ourth week onward. Major differences in clinical signs among
roups were not observed.
One animal in the control group developed fever for ﬁve days.
he rest of the animals recorded rectal temperatures that were
ithin normal range, suggesting that infection may  not have been
evere.
.10. Antibody responses post vaccination and post challenge
Antibody (Ab) responses following vaccination and after
hallenge were measured using CFT. The highest Ab titres
ecorded during vaccination and after challenge are shown in
able 2. Following vaccination seroconversion was observed in
/9 (100%), 5/7(71%) and 3/8 (37.5%) animals immunized with
eat-inactivated, formalin-inactivated and live attenuated (T1/44)
accines.
able 3
accine efﬁcacy of the vaccine formulations.
Vaccination group Vaccine formulation
Heat-inactivated Forma
Number of cattle 9 7 
Average lesion score 0.56 2 
Average Hudson score 0.56 2 
Vaccine efﬁcacy (%) 80.8 31 d Immunopathology 169 (2016) 63–67
Seroconversion was ﬁrst detected one week and three weeks
post vaccination for the animals that received inactivated and
live attenuated vaccine, respectively. The CFT titres were signiﬁ-
cantly higher after vaccination with the inactivated formulations
as compared with the T1/44 vaccine. No signiﬁcant antibody titre
differences were observed between post-vaccination and post-
challenge sera. No correlation between antibody titres before
challenge and pathological scores at post-mortem was observed.
2.11. Pathology and vaccine efﬁcacy
The clinical and pathological observations after challenge in ani-
mals vaccinated with inactivated and T1/44 vaccines are shown
in Table 1. Post-mortem examination revealed pathological lesions
typical of CBPP including consolidation and hepatization of the lung
parenchyma and pleuritis, and well-developed sequestra. Fibrous
adhesions of the parietal and visceral pleurae and kidney conges-
tion were also observed. Mycoplasma were isolated from animals
in the non-vaccinated (7/10), formalin-inactivated (2/7) and T1/44
(3/8) but not in the heat-inactivated group.
The highest number of lung lesions were observed in the con-
trol group (8/10), followed by the formalin-inactivated group (4/7),
heat-inactivated (3/9) and live attenuated groups (1/10), respec-
tively. Average scores for lesion size were higher in non-vaccinated
animals (Table 3). Sequestra formation was  recorded only in two
animals that had been vaccinated with the formalin-inactivated
vaccine.
Vaccine efﬁcacy for the three vaccines, calculated using aver-
age Hudson scores, is shown in Table 3. All the vaccines tested
offered partial protection against CBPP. The protection rate for the
formalin-inactivated, heat-inactivated and live attenuated groups
were 31%, 80.8% and 74.1%, respectively. Higher incidences of bron-
chiopneumonia were observed in the non-vaccinated group than in
the vaccinated groups, an indication that severity of the disease was
less in vaccinated animals. In the non-vaccinated group, more ani-
mals had severe pathology and incidence of mycoplasma isolation
from tissues. Signiﬁcant protection was offered by heat inactivated
(80.8%) and live attenuated (74.1%) mycoplasma and found to be
comparable to the protection rates of 50%–80% observed previously
(Gilbert F. R and Windsor R. 1971; Thiaucourt et al., 2000: Nkando
et al., 2012). Although formalin-inactivated Mmm  had shown pro-
tection previously (Garba & Terry, 1986), protection achieved in our
experiment was very low (31%). We  used the Afadé strain for immu-
nization instead of Gladysdale, but this is unlikely to be the reason
for the different outcome with the previous studies (Garba and
Terry, 1986), since Mmm  strains show little heterogeneity (Fischer
et al., 2013). We used a lower amount of antigen, but unfortunately,
we cannot compare the antibody titers between the two studies,
that might be the reason for the difference in protection rates.
Use of adjuvant in producing a protective immune response to
CBPP by killed mycoplasma is critical. In one experiment (Garba
et al., 1989), animals immunised with incomplete Freund’s adju-
vant were signiﬁcantly better protected after challenge compared
to animals immunized with other adjuvants. The protective capac-
ity of the vaccine therefore depends on the type of adjuvant used,
as also demonstrated for other mycoplasma of the mycoides group
lin-ﬁxed Live attenuated (T1/44) Control
8 10
0.25 1.3
0.75 2.9
74.1
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Mulira et al., 1988). Although Freund’s adjuvant enhances pro-
ection, it is not recommended for animals intended for human
onsumption since they cause spoilage of meat, chronic inﬂamma-
ion and sterile abscess.
The cattle immunized with formalin-ﬁxed mycoplasma had
igher serum titers of speciﬁc antibodies than animals immunized
ith the heat-inactivated mycoplasma, yet were less protected.
his suggests that the formulation plays an important role. We
o not know at this stage the nature of the protective antigens,
nd it seems likely that what we measure in CFT does not corre-
pond to protection. No correlation was evident between Ab titers
nd the severity of CBPP clinical signs or the types and intensity of
ung lesions observed at necropsy and conﬁrms ﬁndings by others
Mamadou et al., 2006; Nkando et al., 2012; Sacchini et al., 2012).
In conclusion, this study demonstrates that three injections of a
accine dose of 3 mg  protein of heat-inactivated Mmm mixed with
reund’s complete adjuvant can offer signiﬁcant protection from
mm  infection. The capacity of an inactivated vaccine to protect
gainst disease indicates that a subunit vaccine or an inactivated
accine against CBPP in a commercially acceptable adjuvant may
e possible. However, careful selection of adjuvant should be done
aking into consideration the potency, safety and ease of application
f the vaccine.
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